Clinical trials: Pulmonary Resistance
NSCLC (Advanced Non-small Cell Lung Cancer)
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
The goal of IMMUNOLIFE2 is to overcome primary resistance to immune checkpoint inhibitors (ICIs), such as pembrolizumab or nivolumab used alone or in combination with chemotherapy, observed in patients with advanced non-small…
- Trial name
- IMMUNOLIFE2 (NCT07001618)
- Testing
- MaaT033 capsule, Cemiplimab, Cisplatin
- Where
- 6 sites in France
- Volunteers
- 162 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic…
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood
- Trial name
- STRATUS (NCT06717243)
- Testing
- Carboplatin/Cisplatin -Etoposide - Atezolizumab
- Where
- 2 sites in United States, Greece
- Volunteers
- 111 people
- Sponsor
- Oncology Center of Biochemical Education And Research
Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
Carboplatin kills cancer cells mainly through induction of DNA damage (drug-DNA adducts). The goal of this clinical trial is to determine if chemoresistance to carboplatin can be identified by measuring carboplatin-induced DNA…
- Trial name
- NCT01261299
- Testing
- Carbon-14-labeled carboplatin
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, Davis
Inflammation, Lung Cancer
Resistance Training in Lung Cancer Patients on Chemotherapy
The purpose of this study is to examine the effectiveness of a resistance training program on reducing systemic inflammation and improving chemotherapy completion in lung cancer patients being treated with curative intent…
- Trial name
- NCT01130714
- Testing
- Exercise
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- East Carolina University
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
- Conditions
- Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases
- Trial name
- NCT00265200
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Louisville
Non Small Cell Lung Cancer, Cervical Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with…
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer
- Trial name
- NCT04925284
- Testing
- XB002, Nivolumab, Bevacizumab
- Where
- 95 sites in United States, Australia and 7 more
- Volunteers
- 269 people
- Sponsor
- Exelixis
Healthcare Associated Pneumonia
Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia
Background The prediction of multi-drug resistant (MDR) pathogens is a key issue in the management of health-care associated pneumonia (HCAP).
- Trial name
- NCT01966796
- Where
- Taiwan
- Volunteers
- 530 people
- Sponsor
- Far Eastern Memorial Hospital
Mycobacterium Abscessus Lung Disease
The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance
Background: Mycobacterium abscessus, one of the most common species of nontuberculous mycobacterium (NTM), poses a significant clinical challenge due to its natural resistance to antibiotics and high treatment failure rates…
- Trial name
- NCT07514364
- Testing
- Rifabutin, No Rifabutin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Obesity, Metabolic Syndrome
Exercise Capacity and Dyspnea in Obese Patients With Metabolic Syndrome: Effects of Weight Loss
Dyspnea is a common complaint in obese patients. The mechanisms behind this dyspnea and the effects of weight loss on dyspnea are not completely understood.
- Trial name
- NCT03035149
- Testing
- Weight Management Program
- Where
- Canada
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
Non-Small-Cell Lung Cancer
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy)…
- Trial name
- CHRYSALIS (NCT02609776)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 69 sites in United States, Australia and 8 more
- Volunteers
- 751 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Tract Infections, Corona Virus Infection
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Non tuberculous mycobacteria (NTM), Burkholdria spp, Aspergillus in the lung are almost impossible to eradicate with conventional antibiotics. In addition COVID-19 has know current treatment.
- Trial name
- NCT03331445
- Testing
- Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Chris Miller
Metabolic Syndrome
Short-term Sugary Beverage Consumption on Glucose Control and Cardiovascular Disease Risk Factors
Our goal is to determine how the addition of sugar-sweetened beverages to the diet affects glucose control, cardiovascular disease risk factors, and pulmonary function in healthy, young adults.
- Trial name
- NCT04118257
- Testing
- Sugary beverage: Fruit juice, Sugary beverage: Soda, Control: Water
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Kansas State University
NSCLC
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
This study is based on the following hypothesis "De novo resistance to EGFR-TKI in EGFR mutation positive patients is related with mutations in EGFR downstream genes".
- Trial name
- NCT01697163
- Volunteers
- 155 people
- Sponsor
- Severance Hospital
Pulmonary Tuberculosis
Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis
The purpose of this study is to evaluate the efficacy and tolerability of the complex therapy of drug-resistant respiratory tuberculosis using the drug Ingaron, a lyophilisate for the preparation of a solution for injection for…
- Trial name
- NCT05359315
- Testing
- Interferon-Gamma
- Where
- Russia
- Volunteers
- 84 people
- Sponsor
- SPP Pharmaclon Ltd.
NSCLC Stage IV
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced Osimertinib-resistant non-squamous non-small cell lung…
- Trial name
- PCA (NCT04136535)
- Testing
- Pemetrexed, Carboplatin, Anlotinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Fudan University
HIV-1-infection, Pneumocystis Pneumonia
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
Cotrimoxazole preventive therapy (CPT) is recommended for prevention of morbidity and mortality due to Pneumocystis pneumonia and other infections in HIV positive patients with low immunity.
- Conditions
- HIV-1-infection, Pneumocystis Pneumonia, Opportunistic Infections, Preventive Therapy
- Trial name
- CoTrimResist (NCT03087890)
- Testing
- Cotrimoxazole
- Where
- 6 sites in Tanzania
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH).
- Trial name
- ILLUMINATE (NCT07318597)
- Testing
- REGN13335
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 99 people
- Sponsor
- Regeneron Pharmaceuticals
Non Small Cell Lung Cancer
T790M Mutation Positive 2nd Line STandard of cAre Registry
The aim of the study is to collect real world information on patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who progressed after first line treatment with an approved Tyrosine-Kinase Inhibitor…
- Trial name
- T-STAR (NCT02368990)
- Where
- 49 sites in United States, China and 7 more
- Sponsor
- AstraZeneca
EGFR-TKI Resistant Mutation
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI.
- Trial name
- NCT02575560
- Testing
- history data
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingdao Central Hospital